7,628.29

+48.22

+0.64%

52,291.03

+520.72

+1.01%

25,637.22

+200.22

+0.79%

2,838.97

+27.13

+0.96%

4.8920

-0.0370

-0.75%

18.72

-0.70

-3.60%

3,975.10

+76.20

+1.95%

77,371.65

-648.35

-0.83%

Crude Oil Dec 26

96.82

-7.30

-7.01%

US Private Equity

10,850.63

-82.20

-0.75%

NasdaqGM - Nasdaq Real Time Price USD

Personalis, Inc. (PSNL)

15.87 +0.05 (+0.28%)

As of 11:31:40 AM EST. Market Open.

Trade PSNL on Coinbase

Loading Chart for PSNL

Chart Range Bar

Interval:

In partnership with ChartIQ

Tempus AI’s Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer

Tempus AI’s Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

Personalis NeXT Personal® Data Showcasing Ultrasensitive MRD to be Presented at ESMO 2026

Personalis (PSNL) Stock Looks Richly Valued As Shares Surge 14x In 3 Years

Personalis (PSNL) Stock Looks Richly Valued As Shares Surge 14x In 3 Years

Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.

Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.

TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight

TEM Stock On Track For Best Week In 4 Months Following Personalis Deal Spotlight

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform

Why Is PSNL Stock Up 5% After-Hours?

Why Is PSNL Stock Up 5% After-Hours?

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

Personalis Accelerates Global Expansion with UKCA Marking for NeXT Personal®, Expanding MRD Access and Biopharma Support in Great Britain

Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?

Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?

Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum

Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum

Mobilize your Website

View Site in Mobile | Classic

Share by: